NCT06143735 2023-11-22
A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting